Antihyperglycemic mechanism of metformin occurs via the AMPK/LXRα/POMC pathway.

ABSTRACT: Metformin is a first-line drug for treating type 2 diabetes. Although metformin is known to phosphorylate AMP-activated protein kinase (AMPK), it is unclear how the glucose-lowering effect of metformin is related to AMPK activation. The aim of this study was to identify the urinary endogenous metabolites affected by metformin and to identify the novel underlying molecular mechanisms related to its anti-diabetic effect. Fourteen healthy male subjects were orally administered metformin (1000 mg) once. First morning urine samples were taken before and after administration to obtain metabolomic data. We then further investigated the anti-diabetic mechanism of metformin in vitro and in vivo. The fluctuation of the metabolite cortisol indicated that the neuroendocrine system was involved in the

SUBMITTER: Cho K 

PROVIDER: S-EPMC4311245 | biostudies-literature | 2015 Jan

REPOSITORIES: biostudies-literature